

RESEARCH ARTICLE

Open Access



Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway

Wei Bing Jing¹, Hongjuan Ji², Rui Jiang³ and Jinlong Wang^{4*}

Abstract

Background: Osteoporosis is a widespread chronic disease characterized by low bone density. There is currently no gold standard treatment for osteoporosis. The aim of this study was to explore the role and mechanism of Astragaloside on osteogenic differentiation of MC3T3-E1 cells.

Methods: MC3T3-E1 cells were divided into control and different dose of Astragaloside (10, 20, 40, 50, and 60 µg/ml). Then, ALP and ARS staining were performed to identify the effects of Astragaloside for early and late osteogenic capacity of MC3T3-E1 cells, respectively. Real-time PCR and western blot were performed to assess the ALP, OCN, and OSX expression. PI3K/Akt signaling pathway molecules were then assessed by Western blot. Finally, PI3K inhibitor, LY294002, was implemented to assess the mechanism of Astragaloside in promoting osteogenic differentiation of MC3T3-E1 cells.

Results: Astragaloside significantly increased the cell viability than the control group. Moreover, Astragaloside enhanced the ALP activity and calcium deposition than the control groups. Compared with the control group, Astragaloside increased the ALP, OCN, and OSX expression in a dose-response manner. Western blot assay further confirmed the real-time PCR results. Astragaloside could significantly increase the p-PI3K and p-Akt expression than the control group. LY294002 partially reversed the promotion effects of Astragaloside on osteogenic differentiation of MC3T3-E1 cells. LY294002 partially reversed the promotion effects of Astragaloside on ALP, OCN, and OSX of MC3T3-E1 cells.

Conclusion: The present study suggested that Astragaloside promoted osteogenic differentiation of MC3T3-E1 cells through regulating PI3K/Akt signaling pathway.

Keywords: Astragaloside, PI3K/Akt pathway, MC3T3-E1 cells, Osteoporosis

* Correspondence: zhifenwen19610615@126.com

Wei Bing Jing and Hongjuan Ji contribute equal to this article as co-first author.

⁴Department of Orthopedics, Hongze District People's Hospital, 102 Dongfeng Road, Hongze District, Huai'an 223100, Jiangsu Province, China
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Osteoporosis is a common systemic bone metabolism disease [1, 2]. It is characterized by reduced bone mass, bone strength, and damage to the bone microstructure, which directly leads to an increase in bone fragility, so the incidence of fractures in patients with osteoporosis increases [3]. As a global health problem, the incidence of osteoporosis has been high [4]. In addition, women face a sharp decline in sex hormones after aging, and the incidence of spondylosis is much higher than that of men [5]. According to statistics, there are 40% of white postmenopausal women suffering from the adverse effects of osteoporosis, and with the development trend of the global population aging, this proportion will keep rising [5]. Among the adverse clinical consequences of osteoporosis, hip fractures and vertebral body fractures are the most serious, and the mortality rate can be as high as 20% after the onset of the disease [6].

At present, the most common clinical treatment plan for osteoporosis is combination medication, which is mainly concentrated and limited to anti-bone resorption and/or promote bone formation [7]. However, most drugs have low sensitivity and many side effects in the population and can even cause complications such as osteonecrosis of the jaw, esophageal irritation, or hypocalcemia [8]. Therefore, looking for more suitable treatment targets, more effective, efficient, safe, and more compliant treatment options are currently urgent problems to be solved.

The pathogenesis of osteoporosis is mainly the disorder of bone homeostasis, that is, the imbalance between osteogenesis and osteoclastogenesis [9]. DangguiBuxue Tang (DBT) is an ancient Chinese herbal decoction that traditionally used to treat menstrual anemia [10]. DBT is used to tonify the liver and kidney, promoting blood flow and removing blood stasis, and strengthen tendons and bones [11].

Astragalus is a popular traditional Chinese medicine commonly used as a constituent in tonic herbal preparations [12]. Astragaloside is the dominant active component of Astragalus. Previous study found that Astragaloside could delay cartilage degeneration [13]. However, whether Astragaloside has a beneficial role in promoting osteogenesis was unknown.

PI3K/Akt signaling pathway is crucial in cell proliferation, differentiation, and adaptation [14]. Previous study found that PI3K/Akt signaling pathway is crucial for osteoblast differentiation in multiple stem cells [15–17]. Thus, we hypothesized that Astragaloside stimulated osteogenic differentiation of MC3T3-E1 cells through PI3K/Akt signaling pathway.

This study aimed to explore whether Astragaloside promoted osteogenic differentiation of pre-osteoblast MC3T3-E1 cells through PI3K/Akt signaling pathway.

Material and methods

Cell source and osteogenic induction

MC3T3-E1 cells were obtained from the cell library of Shanghai Chinese Academy of Sciences (Shanghai, China). Astragaloside was purchased from Xi'an Sobeco Pharmaceutical Technology Company, Limited (purity above 98%, Xi'an, China). Astragaloside was dissolved into DMSO, and the final DMSO concentration did not exceed 0.1% (v/v). MC3T3-E1 was cultured into DMEM/F12 medium supplemented with 10% FBS and 1% penicillin-streptomycin at 37 °C and 5% CO₂. The osteogenic differentiation media comprised of dexamethasone (100 nM), β-glycerophosphate (10 mM), and L-ascorbate (0.2 mM). MC3T3-E1 were seeded at a density of 5×10^5 cells/well in six-well plates. When cells reached approximately 80% confluence, cells were changed to osteogenic differentiation media. Medium was replaced with fresh one every second day.

Bioinformatic analysis of Astragaloside

STITCH database (<http://stitch.embl.de/>) was searched for the potential target genes of Astragaloside. The minimum required interaction score was set as 0.900 and hide the disconnected nodes. Then, these target genes were enriched for gene ontology and KEGG pathway analyses. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and visualization were performed using R (Version 3.5.0).

CCK-8 assay

MC3T3-E1 were incubated at 96 wells at a density of 1×10^4 /ml. Then, MC3T3-E1 cells were incubated with different concentration of Astragaloside. After 3 days of culture, the medium was discharged and 10 μl CCK8 reagents was added. The plates were then incubated for another 2 h. Absorbance at 450 nm was measured using a microplate reader (BioTek microplate reader). The cell viability (%) normalized to the control group was calculated.

Alp

MC3T3-E1 cells were incubated in six-well plates. Then, osteogenic induction medium or osteogenic induction medium containing Astragaloside were added in the plates. ALP staining was performed after 7 days in culture. In brief, medium was removed and washed with PBS for three times. Then, the PBS was discharged and fixed with 4% paraformaldehyde for 15 min. Staining was performed using NBT/BCIP solution until satisfied. Reactions were terminated by the addition of distilled water.

ARS

Medium was removed and washed with PBS for three times. Then, 4% of paraformaldehyde was added for 15 min to fix the MC3T3-E1 cells. Appropriate amount of Alizarin Red dye was added and incubate at room temperature for 30 min. Alizarin Red dye was then discarded and washed with PBS for three times. A light microscope (Olympus) was employed to take pictures. The stained cells were then eluted with 10% cetylpyridinium chloride. After full dissolution, solution absorbance was measured with a microplate reader (BioTek microplate reader) at 405 nm.

Real-time PCR

MC3T3-E1 cells were washed with PBS for three times, and Trizol (Invitrogen, Carlsbad, CA, USA) was added. Chloroform was added to the suspension to give a ratio of 5 : 1 of Trizol to chloroform (v/v). After centrifugation, the RNA-containing aqueous phase was aspirated, and the A260/A280 ratio of all RNA samples was >2.0 as measured by Nanodrop. cDNA was synthesized using the PrimeScript RT reagent kit (Perfect Real Time) (TaKaRa, #RR037A). The qRT-PCR was performed using TB Green® Premix Ex Taq™ (Takara, China). The housekeeping gene GAPDH was used as an internal reference. Primers were as follows: ALP: 5'-AACAGA CAAGCAACCCAAAC-3'; 5'-TAACCCAACGGG CAGAAA-3';

OSX: 5'-CAAATACCC AGATGCTGGGC-3'; 5'-TCCTGGCTGTCCACATGGAC-3';

OCN: 5'-CAGACCTAGCAGACACCATGAG-3'; 5'-CGTCCATACTTTCGAGGCAG-3';

GAPDH: 5'-CCCCGCTACTCCTCCTCCTAAG-3'; 5'-TCCACGACCAGTTGTCCATTCC-3';

Western blot

The plates were washed with PBS three times. Total protein was extracted using a lysis buffer containing PMSF and RIPA (PMSF: RIPA=1: 99). Protein concentration was measured by BCA assay. Extracted proteins were separated by SDS-PAGE (12% acrylamide) and blotted onto PVDF membranes. Blots were blocked with 5% nonfat dry milk for 2 h. PVDF membranes were then incubated for primary antibodies overnight at 4°C. The next day, PVDF membranes were incubated with a second antibody labeled by HRP at room temperature for 1 h. Protein bands were detected using chemiluminescence, and ImageJ was used to quantify Western blot band densities.


Statistical analysis

Results were presented as mean ± standard deviation (SD). All experimental data were analyzed using one-way analyses of variance (ANOVA) with Bonferroni's post hoc test using SPSS 21.0 (IBM Corp., Armonk, NY, USA). P value less than 0.05 was identified as statistically significant. All experiments were performed more than three times.

Results

Astragaloside increased cell viability of MC3T3-E1 cells

CCK-8 assay was performed to evaluate cell viability. Astragaloside increased cell viability in a dose-dependent manner in cultured MC3T3-E1 cells compared to the control group. The most effective was the concentration of Astragaloside at 40 µg/ml (Fig. 1).






Fig. 2 ALP staining in control and Astragaloside-treated MC3T3-E1 cells

Astragaloside increased osteogenic differentiation of MC3T3-E1 cells

To further validate whether Astragaloside could govern the osteogenic differentiation of MC3T3-E1 cells, ALP (Fig. 2) and ARS (Fig. 3) stainings were performed. Results found that Astragaloside increased ALP activity and calcium deposition of MC3T3-E1 cells in a dose-response manner. When the Astragaloside concentration was 40 μg/mL, the ALP activity and calcium deposition was significantly higher than that of other concentration group.

Astragaloside significantly increased osteogenic differentiation markers expression

In order to identify Astragaloside has a positive role in promoting osteogenic differentiation of MC3T3-E1 cells, real-time PCR was performed to real the explore the osteoblast markers expression.

As illustrated in Fig. 4, the ALP, OCN, and OSX mRNA increased 3.52-fold after treatment with Astragaloside compared to the control group ($P < 0.05$). In addition, 50 μg/mL Astragaloside could even more strongly increase ALP, OCN, and OSX expression, which increased 5.67-fold compared to that of the control group, with statistically significant differences ($P < 0.05$).

Moreover, Western Blot results indicated that ALP, OCN, and OSX had the same expression pattern with the real-time PCR assays (Fig. 5).

Bioinformatic analysis of Astragaloside

Through STITCH database, Astragaloside directly target with BMP2, PI3KR1, AKT1, PI3KRA, EGFR, KRAS, and PI3KR3 (Fig. 6 A). Target genes are mainly enriched in transmembrane receptor protein tyrosine kinase signaling pathway, regulation of kinase activity, phosphatidylinositol metabolic process, regulation of protein kinase B signaling, phosphatidylinositol 3-kinase signaling, phosphatidylinositol 3-kinase complex, extrinsic component of membrane, phosphatidylinositol 3-kinase complex, class IA, membrane, cytosol, phosphatidylinositol 3-kinase activity, phosphatidylinositol-4,5-bisphosphate 3-kinase activity, protein phosphatase binding, 1-phosphatidylinositol-3-kinase activity, and 1-phosphatidylinositol-3-kinase regulator activity (Fig. 6 B).

KEGG pathway were as follows: PI3K/AKT signaling pathway, Wnt/β-catenin signaling pathway, HTLV-I infection, Notch signaling pathway, MAPK signaling pathway, Neurotrophin signaling pathway, Long-term potentiation, Dopaminergic synapse, Endocytosis, and Herpes simplex infection (Fig. 6 C).

Astragaloside increased osteogenic differentiation of MC3T3-E1 cells through activating PI3K/Akt signaling pathway

We further analyzed the expression of PI3K, p-PI3K, Akt and p-Akt expressions. It was found that Astragaloside increased the phosphorylation levels of PI3K (p-





Fig. 3 ARS staining in control and Astragaloside-treated MC3T3-E1 cells



PI3K) and AKT (p-AKT) expression, without change of total PI3K and AKT expression. In addition, 40 µg/ml Astragaloside could even more strongly increase phosphorylation levels of PI3K (p-PI3K) and AKT (p-AKT) expression than other dose of Astragaloside (Fig. 7).

LY294002 partially reversed the promotion effects of Astragaloside on osteogenic differentiation of MC3T3-E1 cells

Astragaloside significantly enhanced the osteogenic differentiation of MC3T3-E1 cells. Pretreatment of LY294002, PI3K inhibitor, partially blocked the Astragaloside-induced osteoblastic activity of MC3T3-E1 cells (Fig. 8).


We showed that inhibition of PI3K by LY294002 reduced ALP, Runx2, and OCN mRNA expression in osteoblasts (Fig. 9). Western blot analysis was in agreement with the quantitative real-time PCR (qRT-PCR) results, showing that the protein expression of ALP, Runx2, and OCN was downregulated in the LY294002 group (Fig. 10).



Western blot results found that LY294002 significantly decreased the p-PI3K and p-Akt expressions (Fig. 11).

Discussion

In the present study, we further validated the protective effects of Astragaloside on bone formation. Our results, performed in vitro model and cultured MC3T3-E1 cells, provided assured evidence of the important role of Astragaloside in promoting osteogenic differentiation of MC3T3-E1 cells. The results that Astragaloside activated osteogenic process via promotion of PI3K/Akt pathway and indicated that Astragaloside could be served as a potential therapeutic strategy for bone-related disease.

Osteoporosis is a systemic disease that bone resorption and bone formation typically in a state of negative balance [18]. Deposition of calcium salts is a key step in the fracture healing [19]. In this study, we found that Astragaloside promoted osteogenic differentiation of pre-osteoblast MC3T3-E1 cells in a dose-response manner. The strength of new bone tissue is closely related to the degree of matrix calcification [20]. Alkaline phosphatase








Fig. 8 ALP and ARS staining of the MC3T3-E1 cells in control, Astragaloside, and Astragaloside + LY294002 groups

is a specific marker of early osteogenic differentiation of osteoblasts [21]. Astragaloside significantly increased the ALP activity than control group, which suggested that Astragaloside has a promotion role of bone repair. Astragaloside was extracted from traditional Chinese medicinal plant astragalus membranaceus [22]. Astragaloside possess antioxidant, anti-inflammatory, anti-diabetes, anti-hypertensive, anti-asthma, and anti-fibrotic properties [23–25].

The PI3K/Akt pathway is closely related to bone metabolism [26]. Many signaling molecules selectively activate osteoblasts PI3K/Akt pathway and finally exert their specific effects [27]. Activating the PI3K/Akt pathway can promote the proliferation and differentiation of

osteoblasts [28]. RNA sequencing analysis demonstrated that the P13K/Akt pathway was involved in bone regeneration. Thus, we selected P13K/Akt for further study. RUNX2 is the earliest and most specific marker gene in the process of bone formation. RUNX2 also serves as a marker for osteoblasts differentiation [29]. The RUNX2 homozygous knockout mice correlated with rib aplasia [30, 31]. These finding remind us that RUNX2 is critical for bone formation. In this study, Astragaloside significantly increased the RUNX2 expression and finally promoted osteogenic differentiation of MC3T3-E1 cells.

However, the limitations of this study should not be ignored. Whether Astragaloside regulates other signaling pathways is worth exploring further. The present study





Fig. 9 PCR assay to assess the osteogenic markers in control, Astragaloside, and Astragaloside + LY294002 groups




is based on in vitro experiments, and the results require to be further verified by in vivo experiments. More studies are needed to further clarify the pharmacokinetic variation and drug metabolism.

Conclusion

In conclusion, Astragaloside promoted osteogenic differentiation of MC3T3-E1 cells through regulating

PI3K/Akt signaling pathway. This proposes Astragaloside as a key potential target for primary osteoporosis in the perspective of molecular medicine. Therefore, in future, detailed clinical or in vivo experiments should be performed to support the arguments presented in this study.



Abbreviations

DBT: DangguiBuxue Tang; GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; SD: Standard deviation; ANOVA: One-way analyses of variance

Acknowledgements

Not applicable.

Authors' contributions

WBJ and HJJ conceived the study design. RJ and JLW performed the study and collected the data. WBJ and HJJ prepared the manuscript. RJ and JLW edited the manuscript. All of the listed authors in this article have read and approved the final version of this paper.

Funding

Not applicable.

Availability of data and materials

All of the materials and data in our paper can be available obtained by reasonable request for corresponding author.

Declarations**Ethics approval and consent to participate**

This is a cell line study and thus no ethic approval was needed.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Orthopedics, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang 212300, Jiangsu Province, China. ²Department of Orthopedics, Huai'an Second People's Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai'an, China. ³Department of Orthopedics, Lianshui County People's Hospital, 6 Hongri Road, Huai'an 223400, Jiangsu, P.R. China. ⁴Department of Orthopedics, Hongze District People's Hospital, 102 Dongfeng Road, Hongze District, Huai'an 223100, Jiangsu Province, China.

Received: 18 June 2021 Accepted: 24 August 2021

Published online: 07 October 2021

References

- Zhao Z, Ma X, Ma J, Sun X, Li F, Lv J. Naringin enhances endothelial progenitor cell (EPC) proliferation and tube formation capacity through the CXCL12/CXCR4/PI3K/Akt signaling pathway. *Chem Biol Interact.* 2018;286:45–51. <https://doi.org/10.1016/j.cbi.2018.03.002>.
- Song N, Zhao Z, Ma X, Sun X, Ma J, Li F, et al. Naringin promotes fracture healing through stimulation of angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in osteoporotic rats. *Chem Biol Interact.* 2017;261:11–7. <https://doi.org/10.1016/j.cbi.2016.10.020>.
- You WL, Xu ZL. Curculigolide promotes osteogenic differentiation of ADSCs to prevent ovariectomized-induced osteoporosis. *J Orthop Surg Res.* 2021;16(1):279. <https://doi.org/10.1186/s13018-021-02389-3>.
- Wu JQ, Mao LB, Liu LF, Li YM, Wu J, Yao J, et al. Identification of key genes and pathways of BMP-9-induced osteogenic differentiation of mesenchymal stem cells by integrated bioinformatics analysis. *J Orthop Surg Res.* 2021;16(1):273. <https://doi.org/10.1186/s13018-021-02390-w>.
- Zhang H, Yu Z, Sun F, Jin J. Overexpression of CRABP2 inhibits dexamethasone-induced apoptosis in human osteoblast cells. *J Orthop Surg Res.* 2021;16(1):272. <https://doi.org/10.1186/s13018-021-02386-6>.
- Migliorini F, Maffulli N, Spiezia F, Tingart M, Maria PG, Riccardo G. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. *J Orthop Surg Res.* 2021;16(1):318. <https://doi.org/10.1186/s13018-021-02474-7>.
- Mori Y, Izumiya T, Kurishima H, Kamimura M, Baba K, Mori N, et al. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies. *J Orthop Surg Res.* 2021;16(1):107. <https://doi.org/10.1186/s13018-021-02271-2>.
- Gendelman O, Tripto-Shkolnik L, Vered I, et al. Bisphosphonates related ocular side effects: a case series and review of literature. *Ocul Immunol Inflamm.* 2021:1–5. <https://doi.org/10.1080/09273948.2021.1922705>.
- Tański W, Kosiorowska J, Szymańska-Chabowska A. Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment. *Eur Rev Med Pharmacol Sci.* 2021;25:3557–66. https://doi.org/10.26355/eurrev_202105_25838.
- Chen ST, Lee TY, Tsai TH, Lin YC, Lin CP, Shieh HR, et al. The traditional Chinese medicine DangguiBuxue Tang sensitizes colorectal cancer cells to chemoradiotherapy. *Molecules.* 2016;21(12). <https://doi.org/10.3390/molecules21121677>.
- Li XT, Wang B, Li JL, Yang R, Li SC, Zhang M, et al. Effects of DangguiBuxue Tang, a Chinese herbal medicine, on growth performance and immune responses in broiler chicks. *Biol Res.* 2013;46(2):183–8. <https://doi.org/10.4067/s0716-97602013000200010>.
- She Y, Zhao X, Wu P, Xue L, Liu Z, Zhu M, et al. Astragalus polysaccharide protects formaldehyde-induced toxicity by promoting NER pathway in bone marrow mesenchymal stem cells. *Folia Histochem Cytobiol.* 2021;59(2):124–33. <https://doi.org/10.5603/FHC.a2021.0013>.
- Li H, Peng Y, Wang X, Sun X, Yang F, Sun Y, et al. Astragaloside inhibits IL-1 β -induced inflammatory response in human osteoarthritis chondrocytes and ameliorates the progression of osteoarthritis in mice. *Immunopharmacol Immunotoxicol.* 2019;41(4):497–503. <https://doi.org/10.1080/08923973.2019.1637890>.
- Tang J, Qing MF, Li M, Gao Z. Dexamethasone inhibits BMP7-induced osteogenic differentiation in rat dental follicle cells via the PI3K/AKT/GSK-3 β /catenin pathway. *Int J Med Sci.* 2020;17(17):2663–72. <https://doi.org/10.7150/ijms.44231>.
- Chen X, Chen W, Aung ZM, Han W, Zhang Y, Chai G. LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway. *Bone Joint Res.* 2021;10(4):237–49. <https://doi.org/10.1302/2046-3758.104.bjr-2020-0255.r2>.
- Zhao B, Peng Q, Poon EHL, Chen F, Zhou R, Shang G, et al. Leonurine promotes the osteoblast differentiation of rat BMSCs by activation of autophagy via the PI3K/Akt/mTOR pathway. *Front Bioeng Biotechnol.* 2021;9:615191. <https://doi.org/10.3389/fbioe.2021.615191>.
- Yang XM, Song YQ, Li L, Liu DM, Chen GD. miR-1249-5p regulates the osteogenic differentiation of ADSCs by targeting PDX1. *J Orthop Surg Res.* 2021;16(1):10. <https://doi.org/10.1186/s13018-020-02147-x>.
- Qin Y, Sun R, Wu C, Wang L, Zhang C. Exosome: a novel approach to stimulate bone regeneration through regulation of osteogenesis and angiogenesis. *Int J Mol Sci.* 2016;17(5). <https://doi.org/10.3390/ijms17050712>.
- Rather HA, Jhala D, Vasita R. Dual functional approaches for osteogenesis coupled angiogenesis in bone tissue engineering. *Mater Sci Eng C Mater Biol Appl.* 2019;103:109761. <https://doi.org/10.1016/j.msec.2019.109761>.
- Jacobsen C, Craft AM. Retinoic-acid-induced osteogenesis of hiPSCs. *Nat Biomed Eng.* 2019;3(7):504–6. <https://doi.org/10.1038/s41551-019-0422-3>.
- Zhang Y, Zhang Y, Jin XF, Zhou XH, Dong XH, Yu WT, et al. The role of Astragaloside IV against cerebral ischemia/reperfusion injury: suppression of apoptosis via promotion of P62-LC3-autophagy. *Molecules.* 2019;24(9). <https://doi.org/10.3390/molecules24091838>.
- Yang C, Mo Y, Xu E, Wen H, Wei R, Li S, et al. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model. *Int Immunopharmacol.* 2019;75:105651. <https://doi.org/10.1016/j.intimp.2019.05.036>.
- Lei X, Zhang L, Li Z, Ren J. Astragaloside IV/IncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. *Drug Des Devel Ther.* 2018;12:2785–93. <https://doi.org/10.2147/dddt.s166525>.
- Wei Y, Wu Y, Feng K, Zhao Y, Tao R, Xu H, et al. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF- β /Smads pathway. *J Ethnopharmacol.* 2020;249:112404. <https://doi.org/10.1016/j.jep.2019.112404>.
- Zang Y, Wan J, Zhang Z, Huang S, Liu X, Zhang W. An updated role of astragaloside IV in heart failure. *Biomed Pharmacother.* 2020;126:110012. <https://doi.org/10.1016/j.biopha.2020.110012>.
- Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjehani M, Ahmadzadeh A, et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. *Cell Mol Life Sci.* 2015;72(12):2337–47. <https://doi.org/10.1007/s00018-015-1867-5>.

27. Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. *Am J Cancer Res*. 2015;5(5):1602–9.
28. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. *Front Mol Neurosci*. 2011;4:51. <https://doi.org/10.3389/fnmol.2011.00051>.
29. Teng Z, Zhu Y, Hao Q, Yu X, Teng Y, Yue Q, et al. Long non-coding RNA taurine upregulated gene 1 is downregulated in osteoporosis and influences the osteogenic differentiation of bone marrow mesenchymal stem cells. *PeerJ*. 2021;9:e11251. <https://doi.org/10.7717/peerj.11251>.
30. Zheng L, Tu Q, Meng S, Zhang L, Yu L, Song J, et al. Runx2/DICER/miRNA pathway in regulating osteogenesis. *J Cell Physiol*. 2017;232(1):182–91. <https://doi.org/10.1002/jcp.25406>.
31. Chung CR, Tsuji K, Nifuji A, Komori T, Soma K, Noda M. Micro-CT evaluation of tooth, calvaria and mechanical stress-induced tooth movement in adult Runx2/Cbfa1 heterozygous knock-out mice. *J Med Dent Sci*. 2004;51(1):105–13.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

